Skip to main content

Advertisement

Table 2 Frequency of extraglandular manifestations in female and male pSS patients in the exploratory cohort

From: Difference in clinical presentation between women and men in incident primary Sjögren’s syndrome

  pSS all (n = 199) % (frequency) Women (n = 186) % (frequency) Men (n = 13) % (frequency) p value
Presence of EGM 30% (53/197) 25% (47/185) 46% (6/13) 0.10
No. of EGM (mean ± SD) 0.34 ± 0.64 0.30 ± 0.57 0.85 ± 1.21 0.05
No. of EGM in EGM+ patients (mean ± SD) 1.26 ± 0.59 1.19 ± 0.45 1.83 ± 1.17 0.04
Extraglandular manifestationsa
Articular
 Arthritis 14% (28/197) 14% (26/184) 15% (2/13) 1.00
Pulmonary
 Interstitial lung disease 1% (2/196) 0% (0/183) 15% (2/13) 0.004
 Alveolitis 0.5% (1/197) 0% (0/184) 8% (1/13) 0.07
Renal
 Interstitial nephritis 0.5% (1/197) 0.5% (1/184) 0% (0/13) 1.00
Cutaneous
 Cutaneous vasculitis 4% (7/195) 2% (4/182) 23% (3/13) 0.007
Neurological
 Polyneuropathy 4% (8/195) 4% (7/182) 8% (1/13) 0.43
 Mononeuritis 0.5% (1/197) 0.5% (1/184) 0% (0/13) 1.00
 CNS involvement 1% (2/197) 1% (2/184) 0% (0/13) 1.00
Constitutional
 Recurrent fever 7% (14/197) 7% (12/184) 15% (2/13) 0.23
Lymphadenopathy
 Enlarged lymph nodes 1% (4/197) 2% (3/184) 8% (1/13) 0.24
Muscular
 Myositis 2% (3/197) 0.5% (1/184) 0% (0/13) 1.00
  1. aExtraglandular manifestations evaluated to estimate the EULAR Sjögren’s syndrome disease activity index (ESSDAI)
  2. Bold values indicate statistically significant findings (p < 0.05)